Critical Contrast: LeMaitre Vascular (LMAT) & BIOLASE (BLTI)
LeMaitre Vascular (NASDAQ: LMAT) and BIOLASE (NASDAQ:BLTI) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitabiliy, earnings, dividends and valuation.
Insider & Institutional Ownership
66.4% of LeMaitre Vascular shares are owned by institutional investors. 23.7% of LeMaitre Vascular shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of recent ratings and target prices for LeMaitre Vascular and BIOLASE, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
LeMaitre Vascular presently has a consensus price target of $25.71, indicating a potential downside of 11.30%. Given LeMaitre Vascular’s higher possible upside, equities analysts plainly believe LeMaitre Vascular is more favorable than BIOLASE.
This table compares LeMaitre Vascular and BIOLASE’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
LeMaitre Vascular pays an annual dividend of $0.22 per share and has a dividend yield of 0.8%. BIOLASE does not pay a dividend. LeMaitre Vascular pays out 36.7% of its earnings in the form of a dividend.
Earnings & Valuation
This table compares LeMaitre Vascular and BIOLASE’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|LeMaitre Vascular||$93.03 million||5.86||$21.22 million||$0.60||48.32|
LeMaitre Vascular has higher revenue and earnings than BIOLASE.
LeMaitre Vascular beats BIOLASE on 9 of the 10 factors compared between the two stocks.
About LeMaitre Vascular
LeMaitre Vascular, Inc. is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment. The Company’s product lines include valvulotomes, balloon catheters, carotid shunts, biologic vascular patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, prosthetic vascular grafts, biologic vascular grafts and powered phlebectomy devices. Its portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt, VascuTape Radiopaque Tape and the XenoSure biologic patch.
BIOLASE, Inc. (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. It offers two categories of laser system products: WaterLase (all-tissue) systems and Diode (soft tissue) systems. Its brand, WaterLase, uses a combination of water and laser energy to perform procedures performed using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers its Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed.
Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with MarketBeat.com's FREE daily email newsletter.